Stockreport

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Puma Biotechnology Inc  (PBYI) 
Last puma biotechnology inc earnings: 2/20 04:07 pm Check Earnings Report
US:NYSE Investor Relations: pumabiotechnology.com/ir.html
PDF LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA™-Brea [Read more]